JP Morgan Reinstates Overweight on Amneal Pharmaceuticals, Announces $22 Price Target

Benzinga · 1d ago
JP Morgan analyst Chris Schott reinstates Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and announces $22 price target.